Group items tagged

The goal of the K12 Institutional Career Development Program in HIV-related Heart, Lung, Blood, and Sleep (HLBS) research is to encourage institutions to develop and sustain programs that support inter-disciplinary, intensive mentored research training and career development for junior PhDs and MDs in AIDS co-morbidities as well as cell and gene therapies for HIV cure and prevention of HIV transfusion transmission.

The purpose of this Funding Opportunity Announcement (FOA) is to foster research on human long non-coding RNAs (lncRNAs) to understand their roles in controlling the gene regulatory networks underpinning normal Heart, Lung, Blood and Sleep (HLBS) homeostatic and disease processes. 

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), the Division of Epidemiology, Statistics, and Prevention Research intends to solicit proposals to award an Indefinite Delivery Indefinite Quantity (IDIQ) contract to an organization to conduct various studies focusing on a spectrum of health effects in men, women, and children that rely on quantification of analytes in biological specimens such as blood, urine, adipose tissue, follicular fluids, and seminal fluids.  The Division needs a variety of banked specimens analyzed for concentrations of various hormone levels, dietary biomarkers, and indicators of metabolic function among other analytes.

A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-16-006) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-16-007) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization.

In 2017, the Pancreatic Cancer Action Network will invest $12.8 million in innovative research related to pancreatic cancer, a 33 percent increase over 2016. This investment includes both the network's competitive, peer-reviewed Research Grants Program and its internal research initiatives. To that end, the network has issued an RFA for its Early Detection Targeted Grant program, through which grants of up to $1 million over four years will be awarded to support ancillary research studies that identify promising blood biomarkers or imaging approaches with the potential to facilitate the use of specimens and/or participants in a cohort of new-onset diabetics and to validate components of a protocol for the early detection of pancreatic ductal adenocarcinoma.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-​effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC&'s current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. APPLY FOR A GRANT Sign up for our newsletter

The objective of this research career program is to create a national Consortium that focuses on career development of the next generation of biomedical investigators in glycosciences. The ultimate goal of the Consortium is to transform and democratize glycosciences from a super-specialized research domain into the mainstream of biology and clinical translation such that glycans become an integral component of future scholars'/investigators' scientific thinking, thus creating a pathway for major scientific breakthroughs specifically in heart, lung, blood and sleep (HLBS) sciences.    

Attention veterinarians, lab technicians, animal technicians, and all who work with laboratory animals: The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) now is accepting proposals for the 2014 Science-based Refinement Awards (formerly the Animal Welfare Enhancement Awards). The focus of these awards is to elicit scientific evidence to support the enhancement of the housing, handling and/or experimental situations for laboratory animals. Studies may, for example, examine: how physiological and behavioral stress responses to common husbandry (e.g., capture) and traditional treatment procedures (e.g., gavage, injection, blood collection) can be reduced or eliminated (e.g., by training the subjects to cooperate rather than resist); whether animals caged at different tier levels show different physiological and behavioral stress responses when being approached by personnel, and how these responses can be minimized or avoided; whether the presence of a compatible companion buffers physiological and behavioral stress responses to experimental situations (e.g., enforced restraint); whether animals kept in legally minimum-sized cages benefit from a moderate increase in space that is (a) empty versus (b) structured in species-appropriate ways (e.g., shelter, visual blind, perch, platform, PVC tube).

The purpose of this funding opportunity announcement (FOA) is to support projects that will generate reference profiles of both short and long non-coding regulatory extracellular RNAs (exRNA), including any environmentally-derived exRNA (e.g. from diet, microbiome), from a diversity of healthy human body fluids including blood, saliva, urine, breast milk, semen, amniotic fluid, cerebrospinal fluid, ascites and pleural effusions. Studies using existing human biospecimen collections are strongly encouraged. This FOA is only for studies related to human samples; animal or other non-human disease model studies are not responsive to this FOA.

The Chemical and Biological Separations (CBS) program supports fundamental research on novel methods and materials for separation processes.  These processes are central to the chemical, biochemical, materials, energy, and pharmaceutical industries.  A fundamental understanding of the interfacial, transport, and thermodynamic behavior of multiphase chemical systems as well as quantitative descriptions of processing characteristics in the process-oriented industries is critical for efficient resource management and effective environmental protection.  The program encourages proposals that address emerging research areas and technologies, have a high degree of interdisciplinary thought coupled with knowledge creation, and integrate education and research. Research topics OF PARTICULAR INTEREST in CBS include fundamental molecular-level work on: Nanostructured materials for separations Biorenewable resource separation processes Purification of drinking water Field (flow, magnetic, electrical) induced separations Separation of molecular constituents from blood The duration of unsolicited awards is generally one to three years.  The average annual award size for the program is $80,000.  Proposals requesting a substantially higher amount than this, without prior consultation with the Program Director, may be returned without review.  Small equipment proposals of less than $100,000 will also be considered and may be submitted during the annual submission window. 

The National Heart, Lung, and Blood Institute (NHLBI), NIH is seeking qualified sources to perform a follow up to the Women's Health Initiative (WHI) Study. NHLBI anticipates the issuance of a request for proposals (NHLBI-CSB-WH-2016-01-CM) on or about August 21, 2014 for the WHI Regional Centers .

This Funding Opportunity Announcement (FOA) issued by the Office of Behavioral and Social Sciences Research (OBSSR) and the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of General Medical Sciences (NIGMS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) at the National Institutes of Health, encourages Research Project Grant (R01) applications from institutions/organizations that propose to develop basic and applied projects utilizing systems science methodologies relevant to human behavioral and social sciences and health. This FOA is intended to encourage a broader scope of topics to be addressed with systems science methodologies, beyond those encouraged by existing open FOAs. Research projects applicable to this FOA are those that are either applied or basic in nature (including methodological development), have a human behavioral and/or social science focus, and feature systems science methodologies

The National Institute on Drug Abuse (NIDA) will solicit proposals from qualified organizations capable of maintaining and expanding the NIDA Center for Genetic Studies. In this effort, the contractor will be required to: (1) Receive de-identified clinical, diagnostic, pedigree structure, environmental exposure information and other phenotypic data along with blood samples or other biospecimens from funded grants and/or contracts supporting research on the genetics of addiction and addiction vulnerability; (2) Process these data and materials to create databases, serum, DNA, RNA, and cell lines; (3) Widely distribute all data and materials in the NIDA Human Genetics Initiative to qualified investigators in the scientific community in a cost effective manner; (4) Maintain storage of data and biomaterials; (5) As stipulated by NIDA staff, perform microarray typing on pre-existing and/or new de-identified biospecimens; (6) As stipulated by NIDA staff, perform high-throughput sequencing on pre-existing and/or new de-identified biospecimens for genomic and/or epigenomic analyses; (7) Support the creation of reprogrammed cellular derivatives, such as induced pluripotent stem cells (iPSCs) to facilitate the molecular and cellular study of brain development and addiction processes; (8) Create a cyberinfrastructure that enables interoperability and full access to distributed data, software and other information science resources as well as research summaries and outbound links for all addiction related studies available through the NIH database of Genotype and Phenotype (dbGaP) system; and (9) Faciliate NIDA genetic studies data (both genotype and phenotype) being uploaded into NIH databases such as BioSample, and the dbGaP systems.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in older adults with T1D.

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

This Funding Opportunity Announcement (FOA) is to support studies that are essential, yet also sufficient, for investigators to make definitive decisions about the designs of important clinical trials within NHLBI's mission, the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial.

 The goal of the Consortium is to translate advances in progenitor cell biology towards application to heart, lung, and blood diseases. The initiative will focus on the use of progenitor cell-based disease models to understand disease mechanisms, the development of novel therapies, and the application of cell-based therapies for the treatment of diseases.

The purpose of the AETC NCCC is to supply health care providers with a national resource to obtain timely and appropriate responses to clinical questions relating to: 1) the treatment of people living with HIV (PLWH) and those at high risk for HIV infection; 2) health care worker exposure to HIV and other blood borne pathogens (e.g., viral hepatitis); 3) the treatment of pregnant women living with HIV, and their exposed infants, and a perinatal referral service to connect them with HIV-experienced care providers; and 4) PLWH with behavioral health and/or substance abuse issues. 

The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, support during the UH2 phase is for the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using human iPSC-derived cells representing sensory/pain neurons, brain regions, and other tissues involved in nociception, addiction and/or overdose, including tissue models of the blood-brain barrier (BBB). Support during the UH3 is for implementation of drug screens using the 3D tissue models developed during the UH2 phase. Please limit this field to a brief description of to page in length. Brevity is appreciated. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative